Literature DB >> 9081357

Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis.

G Flamini1, G Curigliano, C Ratto, A Astone, G Ferretti, P Nucera, L Sofo, A Sgambato, A Boninsegna, F Crucitti, A Cittadini.   

Abstract

p53 overexpression was studied by immunohistochemistry in 96 consecutive colorectal cancer patients, subdividing positive specimens according to two staining patterns: cytoplasmic or nuclear. Forty-seven per cent of the cases were p53 positive, a significant correlation being found with Dukes' stage (P = 0.0036). A prevalence of nuclear staining was observed in Dukes' B and cytoplasmic in Dukes' D stages. After 36 months, 23% of the patients had a recurrence, and 45% were p53 positive, all Dukes' C-D stage with cytoplasmic staining. The Kaplan-Meier curve showed a significant correlation between p53 cytoplasmic staining and disease-free survival period (P = 0.002). With respect to disease-free survival, the Cox proportional hazard regression test, comparing p53 positivity with Dukes' stage, showed the latter to be the most significant variable. In our series of patients, advanced Dukes' stage tumours were localised in the right colon, where a higher percentage of p53 positivity (67% versus 40% of the left side), as well as a higher frequency of cytoplasmic staining was observed. In conclusion, from the data obtained, a strong correlation between p53 cytoplasmic staining and patient prognosis is clearly indicated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9081357     DOI: 10.1016/0959-8049(95)00625-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma.

Authors:  Dan-ping Zhao; Xiao-wen Ding; Jia-ping Peng; Yi-xiong Zheng; Su-zhan Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2005-12       Impact factor: 3.066

2.  Quantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in nonsmall cell lung cancer.

Authors:  Chun-I Wang; Kun-Yi Chien; Chih-Liang Wang; Hao-Ping Liu; Chia-Chen Cheng; Yu-Sun Chang; Jau-Song Yu; Chia-Jung Yu
Journal:  Mol Cell Proteomics       Date:  2012-07-25       Impact factor: 5.911

3.  Prognostic significance of p53-expression in colorectal carcinoma as measured by a luminometric immunoassay.

Authors:  Oliver Lotter; Amro Amr; Farouk Safi
Journal:  Ger Med Sci       Date:  2010-10-08

4.  Nuclear to cytoplasmic shift of p33(ING1b) protein from normal oral mucosa to oral squamous cell carcinoma in relation to clinicopathological variables.

Authors:  Jin-Ting Zhang; Da-Wei Wang; Qing-Xing Li; Zhen-Long Zhu; Ming-Wei Wang; Dong-Sheng Cui; Yan-Hong Yang; Yu-Xin Gu; Xiao-Feng Sun
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-06       Impact factor: 4.553

5.  Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.

Authors:  Mirna Lechpammer; Josip Lukac; Stanislav Lechpammer; Dujo Kovacević; Massimo Loda; Zvonko Kusić
Journal:  Int J Colorectal Dis       Date:  2003-11-21       Impact factor: 2.571

Review 6.  Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.

Authors:  Jessica Weekes; Alfred King-Yin Lam; Sabe Sebesan; Yik-Hong Ho
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

Review 7.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

Review 8.  The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment.

Authors:  Natasja L de Vries; Marloes Swets; Alexander L Vahrmeijer; Marianne Hokland; Peter J K Kuppen
Journal:  Int J Mol Sci       Date:  2016-06-29       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.